Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease

Journal of Nephrology

Volumn 21, Issue 6, 2008, Pages 900-908

  Dummer, Claus D ^a   Thome, Fernando S ^b   Zingano, Bianca ^a   Lindoso, Alberto ^a   Veronese, Francisco V ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Chronic kidney disease; Inflammation; Nutritional status; Oxidative stress; Statin

Indexed keywords

C REACTIVE PROTEIN; CARBONYL DERIVATIVE; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SCAVENGER; SIMVASTATIN; TOTAL RADICAL TRAPPING ANTIOXIDANT POTENTIAL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METABOLIC REGULATION; NUTRITIONAL STATUS; OXIDATIVE STRESS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT RESPONSE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; METABOLISM; MIDDLE AGED; PHOTOMETRY; PHYSIOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CREATININE; CROSS-OVER STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; NUTRITIONAL STATUS; OXIDATIVE STRESS; RETROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 62749179046     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
2. United States Renal Data System. USRDS 2006 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. Available at: http://www.usrds.org/2006/ref/ H_morte_06.pdf. Last accessed October 24, 2008.
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-2219.
4. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003;14:1927-1939.
5. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737-1745.
6. Yeun JY, Kaysen GA. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin Nephrol Hypertens. 2000;9:621-630.
7. Papagianni A, Kalovoulos M, Kirmizis D, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18:113-119.
8. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297-304.
9. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557-1563.
10. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23.
11. Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994;233:357-363.
12. a, Pinhais. Programa e Resumos. São Paulo: FESBE, 2003 No. 07.001-CD-ROM.
13. Lissi E, Pascual C, Del Castillo MD. Luminol luminescence induced by 2,2′-azo-bis(2-amidinopropane) thermolysis. Free Radic Res Commun. 1992;17:299-311.
14. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC. A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transplant. 1999;14:1732-1738.
15. Montgomery DC. Design and analysis of experiments. 3th ed. New York: Wiley; 1976:134-175.
16. Koenig W. Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int Suppl. 2003;84:S58-S61.
17. Wang AY, Woo J, Lam CW, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol. 2003;14:1871-1879.
18. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
19. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68:237-245.
20. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997;272:20313-20316.
21. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int Suppl. 2001;78:S25-S31.
22. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39:1213-1217.
23. van den Akker JM, Bredie SJ, Diepeveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003;16:238-244.
24. Diepeveen SH, Verhoeven GW, Van Der Palen J, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med. 2005;257:438-445.
25. Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006;21:337-344.
26. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005;96:1290-1292.
27. Di Lullo L, Addesse R, Comegna C, et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv Ther. 2005;22:601-612.
28. Raj DS, Dominic EA, Pai A, et al. Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int. 2005;68:2338-2344.
29. Trip MD, van Wissen S, Smilde TJ, Hutten BA, Stalenhoef AF, Kastelein JJ. Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. Am J Cardiol. 2003;91:604-606.
30. Nascimento MM, Suliman ME, Bruchfeld A, et al. The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol Dial Transplant. 2004;19:3112-3116.
31. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant. 2001;16:335-340.
32. Gutierrez LL, Mazzotti NG, Araujo AS, et al. Peripheral markers of oxidative stress in chronic mercuric chloride intoxication. Braz J Med Biol Res. 2006;39:767-772.
33. Baber U, Toto RD, Lemos JA. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J. 2007;153:471-477.